We are live on
!
Find out more
LCM
Lynx1 Capital Management Portfolio holdings
AUM
$633M
1-Year Est. Return
173.22%
This Fund
S&P 500
This Quarter
Est. Return
-24.44%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$108M
AUM Growth
-$6.91M
(-6%)
Cap. Flow
+$21.9M
Cap. Flow
% of AUM
20.36%
Top 10 Holdings %
Top 10 Hldgs %
98.47%
Holding
14
New
4
Increased
6
Reduced
3
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
+$12.2M |
| 2 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
+$7.62M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$5.47M |
| 4 |
MRUS
Merus
MRUS
|
+$2.95M |
| 5 |
PVLA
Palvella Therapeutics
PVLA
|
+$2.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$8.64M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
+$3.25M |
| 3 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$562K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRUS
1
DELISTED
Merus
MRUS
| $23.6M | 21.94% |
893,527
+110,129
| +14% | +$2.95M |
|
|
BLU
2
DELISTED
BELLUS Health Inc.
BLU
| $19.6M | 18.22% |
2,851,588
+848,474
| +42% | +$5.47M |
|
|
ALPN
3
DELISTED
Alpine Immune Sciences Inc
ALPN
| $13.3M | 12.37% |
1,484,693
+222,766
| +18% | +$1.93M |
|
|
PRDS
4
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $11.9M | 11.01% |
1,642,834
+1,241,241
| +309% | +$12.2M |
|
|
5
Travere Therapeutics
TVTX
$5.33B
| $10.6M | 9.85% |
411,680
-325,381
| -44% | -$8.64M |
|
|
KNTE
6
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $7.8M | 7.24% |
+692,508
| New | +$7.62M |
|
|
IMGN
7
DELISTED
Immunogen Inc
IMGN
| $7.35M | 6.82% |
1,543,259
-586,272
| -28% | -$3.25M |
|
|
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
| $4.32M | 4.01% |
1,388,505
+163,537
| +13% | +$515K |
|
|
THRX
9
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $4.11M | 3.82% |
356,827
-52,531
| -13% | -$562K |
|
|
PVLA
10
Palvella Therapeutics
PVLA
$1.98B
| $3.44M | 3.2% |
14,204
+9,413
| +196% | +$2.47M |
|
|
JBIO
11
Jade Biosciences
JBIO
$1.22B
| $1.23M | 1.14% |
+1,914
| New | +$743K |
|
12
Passage Bio
PASG
$15.9M
| $327K | 0.3% |
+5,275
| New | +$435K |
|
|
OTIC
13
DELISTED
Otonomy, Inc.
OTIC
| $72K | 0.07% |
30,000
| – | – |
|
|
ELEV
14
DELISTED
Elevation Oncology
ELEV
| $25K | 0.02% |
+10,000
| New | +$40.1K |
|
Similar funds
SWM
RFA
WA
AMM
EIM
SWP
ACM
BI
Lynx1 Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Lynx1 Capital Management held 14 positions worth $108M, down 6% from $115M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Lynx1 Capital Management deployed $21.9M of net new capital in Q1 2022, opening 4 new positions and adding to 6 existing holdings. Its largest new stake was Kinnate Biopharma Inc. Common Stock: 692,508 shares worth $7.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $8.64M trimmed.
- Lynx1 Capital Management's largest Q1 2022 buy was Kinnate Biopharma Inc. Common Stock: 692,508 shares worth $7.8M.
- Lynx1 Capital Management added most to Pardes Biosciences, Inc. Common Stock in Q1 2022, an estimated $12.2M increase.
- Lynx1 Capital Management's biggest Q1 2022 reduction was Travere Therapeutics, cutting an estimated $8.64M.
- Lynx1 Capital Management's ten largest holdings make up 98% of its $108M portfolio in Q1 2022.
- Lynx1 Capital Management opened 4 new positions and closed 0 in Q1 2022.
- Lynx1 Capital Management's portfolio value fell 6% quarter-over-quarter to $108M.
Based on Lynx1 Capital Management's 13F filing for Q1 2022, filed 16 May 2022.